Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists

Nature
Stéphane ProstPhilippe Leboulch

Abstract

Whether cancer is maintained by a small number of stem cells or is composed of proliferating cells with approximate phenotypic equivalency is a central question in cancer biology. In the stem cell hypothesis, relapse after treatment may occur by failure to eradicate cancer stem cells. Chronic myeloid leukaemia (CML) is quintessential to this hypothesis. CML is a myeloproliferative disorder that results from dysregulated tyrosine kinase activity of the fusion oncoprotein BCR-ABL. During the chronic phase, this sole genetic abnormality (chromosomal translocation Ph(+): t(9;22)(q34;q11)) at the stem cell level causes increased proliferation of myeloid cells without loss of their capacity to differentiate. Without treatment, most patients progress to the blast phase when additional oncogenic mutations result in a fatal acute leukaemia made of proliferating immature cells. Imatinib mesylate and other tyrosine kinase inhibitors (TKIs) that target the kinase activity of BCR-ABL have improved patient survival markedly. However, fewer than 10% of patients reach the stage of complete molecular response (CMR), defined as the point when BCR-ABL transcripts become undetectable in blood cells. Failure to reach CMR results from the inability ...Continue Reading

References

Jun 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hugues de LavalladeDavid Marin
Apr 30, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Douglas J KominskyNatalie J Serkova
Oct 27, 2009·Clinica Chimica Acta; International Journal of Clinical Chemistry·Olivia RothBenjamin Maneglier
Mar 5, 2010·EMBO Molecular Medicine·Andrea HoelblVeronika Sexl
Mar 23, 2010·European Journal of Pharmacology·Desheng Lu, Dennis A Carson
Dec 16, 2010·The Journal of Clinical Investigation·Amie S CorbinBrian J Druker
Jan 13, 2012·Nature Reviews. Cancer·Long V NguyenConnie J Eaves
Mar 20, 2013·Current Opinion in Hematology·Jinwei Du, Yu-Chung Yang

❮ Previous
Next ❯

Citations

Feb 13, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Mengqi YangPeng Huang
Feb 4, 2016·The Cancer Journal·Priyanka A Pophali, Mrinal M Patnaik
Jan 20, 2016·Bulletin du cancer·Nicolas MagnéStéphane Vignot
Oct 16, 2015·Cancer Cell·Beth Apsel Winger, Neil P Shah
Mar 15, 2016·Biochemical and Biophysical Research Communications·Olivier GoupilleStany Chrétien
Sep 4, 2015·Nature·Tessa Holyoake, David Vetrie
Jan 30, 2016·American Journal of Hematology·Paolo BernasconiCeleste Calvello
Nov 13, 2015·The New England Journal of Medicine·Josephine M Egan
May 12, 2016·Archives of Toxicology·Christos V RizosMoses S Elisaf
Jun 10, 2016·Chemical Communications : Chem Comm·Geetha Bolla, Ashwini Nangia
Feb 4, 2016·Chemical Biology & Drug Design·Bahman YousefiNosratollah Zarghami
Jun 9, 2016·International Journal of Molecular Sciences·Idoia García-RamírezIsidro Sánchez-García
Apr 27, 2016·Cancer Science·Shoichiro Takeishi, Keiichi I Nakayama
Oct 7, 2016·Science·Cristina Morales TorresPaola Scaffidi
Oct 21, 2016·Antioxidants & Redox Signaling·Sarah TessierValérie Lallemand-Breitenbach
Dec 28, 2016·Cancer·Philippe RousselotUNKNOWN French CML Group
Dec 27, 2016·Experimental Hematology·Cassie J Clarke, Tessa L Holyoake
Feb 6, 2017·Blood·Tessa L Holyoake, David Vetrie
May 1, 2017·Chemical Biology & Drug Design·Vahid Shafiei-IrannejadNosratollah Zarghami
Jul 26, 2017·Cancer·Laurence LegrosUNKNOWN French Intergroup for Chronic Myeloid Leukemias
Mar 10, 2018·Expert Review of Hematology·Fulvio MassaroMassimo Breccia
Oct 6, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Bahman YousefiNasser Samadi
Nov 16, 2017·Blood·Elodie GrockowiakVéronique Maguer-Satta
Jun 19, 2018·Leukemia & Lymphoma·Philippe Rousselot
Jul 28, 2018·Toxicological Sciences : an Official Journal of the Society of Toxicology·Andrew D PattersonJeffrey M Peters
Jan 18, 2018·Leukemia & Lymphoma·Jieke CuiPing Zou
Aug 30, 2018·International Journal of Hematology·Yosuke Minami
Nov 30, 2018·Angewandte Chemie·Ashwini K Nangia, Gautam R Desiraju
Dec 10, 2017·Hematology·Ravi Bhatia
Apr 25, 2019·Stem Cells Translational Medicine·Haojian Zhang, Shaoguang Li
Oct 21, 2015·Nature Reviews. Clinical Oncology·Francesco BertoliniGauthier Bouche
Jun 10, 2016·Nature·Sheela A AbrahamTessa L Holyoake
Dec 2, 2017·Nature Reviews. Cancer·Hugues de Thé
Jul 5, 2019·British Journal of Haematology·Marc G BergerUNKNOWN (France Intergroupe des Leucémies Myéloïdes Chroniques)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Related Papers

Postȩpy higieny i medycyny doświadczalnej
Olga Grzybowska-IzydorczykTadeusz Robak
Clinical Lymphoma & Myeloma
Emma Nicholson, Tessa Holyoake
Current Hematologic Malignancy Reports
Ross Kinstrie, Mhairi Copland
© 2021 Meta ULC. All rights reserved